Skip to contentC
Collegium Pharmaceutical, Inc
C
COLLCollegium Pharmaceutical, Inc Q3 2018 · 10-Q
Revenue$70.18M$70.18M+487.2% vs Q3 2017 Net Income-$16.50M-$16.50MN/M vs Q3 2017 EPS Diluted-$0.50-$0.50N/M vs Q3 2017 Operating Income-$11,186,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Collegium Pharmaceutical, Inc · CIK 1267565 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$39,117,000N/M Margins · derivedOperating margin-15.9%+96.4 pt vs Q3 2017
Net margin-23.5%+87.5 pt vs Q3 2017
ended Sep 30, 2018 · filed Nov 8, 2018 · 39 d after period end